Experienced in HER2 Negative Breast Cancer

Dr. Rebecca L. Aft

Surgical Oncology | General Surgery
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
Accepting New Patients
Experienced in HER2 Negative Breast Cancer
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rebecca Aft is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Aft is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Mastectomy, and Lymphadenectomy. Dr. Aft is currently accepting new patients.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of HER2 Negative Breast Cancer.

Specialties
Surgical Oncology
General Surgery
Licenses
Surgery in MO
Hospital Affiliations
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drug: LY3484356
Study Phase: Phase 1
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Procedure
Study Phase: Phase 3
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer
Enrollment Status: Terminated
Publish Date: August 17, 2025
Intervention Type: Drug, Procedure, Device
Study Drug: LS301
Study Phase: Phase 1/Phase 2
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab
Study Phase: Phase 1/Phase 2
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
A Phase 1B Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in ER+, HER2- Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Biological, Procedure
Study Drug: Mammaglobin-A DNA Vaccine
Study Phase: Phase 1
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Conjugated Estrogens/Bazedoxifene
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Enrollment Status: Terminated
Publish Date: May 28, 2024
Intervention Type: Device, Biological, Drug, Procedure
Study Drugs: Durvalumab, Neoantigen DNA vaccine
Study Phase: Phase 1
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Procedure
Study Drugs: Palbociclib, Letrozole, Fulvestrant, Goserelin
Study Phase: Phase 2
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Drug, Procedure
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Enrollment Status: Terminated
Publish Date: September 29, 2021
Intervention Type: Procedure, Drug, Genetic, Biological
Study Phase: Phase 2
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: June 25, 2020
Intervention Type: Device, Behavioral, Procedure, Other
Study Phase: Phase 2
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Enrollment Status: Withdrawn
Publish Date: August 16, 2018
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 1
View 16 Less Clinical Trials

73 Total Publications

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 10, 2025
Similar Doctors
Julie A. Margenthaler
Advanced in HER2 Negative Breast Cancer
Dr. Julie A. Margenthaler
Surgical Oncology | General Surgery
Advanced in HER2 Negative Breast Cancer
Dr. Julie A. Margenthaler
Surgical Oncology | General Surgery

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-4699
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Julie Margenthaler is a Surgical Oncologist and a General Surgeon in Saint Louis, Missouri. Dr. Margenthaler is rated as an Elite provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Intraductal Papilloma, Mastectomy, and Lymphadenectomy. Dr. Margenthaler is currently accepting new patients.

Advanced in HER2 Negative Breast Cancer
Dr. Tonya M. Martin-Dunlap
General Surgery
Advanced in HER2 Negative Breast Cancer
Dr. Tonya M. Martin-Dunlap
General Surgery

Mercy Clinic St Louis Cancer And Breast Institute LLC

10050 Kennerly Rd, Suite 1500, 
Saint Louis, MO 
 (11.0 miles away)
314-525-1545
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tonya Martin-Dunlap is a General Surgeon in Saint Louis, Missouri. Dr. Martin-Dunlap is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Mastectomy. Dr. Martin-Dunlap is currently accepting new patients.

Advanced in HER2 Negative Breast Cancer
Dr. Abigail W. Hoffman
General Surgery
Advanced in HER2 Negative Breast Cancer
Dr. Abigail W. Hoffman
General Surgery

Mercy Clinic St Louis Cancer And Breast Institute LLC

15945 Clayton Rd, Suite 120, 
Ballwin, MO 
 (17.7 miles away)
636-256-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Abigail Hoffman is a General Surgeon in Ballwin, Missouri. Dr. Hoffman is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Intraductal Papilloma. Dr. Hoffman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aft's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile